Would Big Pharma Pay for the Wall?

Indonesia Berita Berita

Would Big Pharma Pay for the Wall?
Indonesia Berita Terbaru,Indonesia Berita utama
  • 📰 WSJ
  • ⏱ Reading Time:
  • 1 sec. here
  • 2 min. at publisher
  • 📊 Quality Score:
  • News: 4%
  • Publisher: 63%

The government shutdown over funding for the border wall may start to put a dent in the prodigious cash flows of big drug and biotech firms

Berita ini telah kami rangkum agar Anda dapat membacanya dengan cepat. Jika Anda tertarik dengan beritanya, Anda dapat membaca teks lengkapnya di sini. Baca lebih lajut:

WSJ /  🏆 98. in US

Indonesia Berita Terbaru, Indonesia Berita utama

Similar News:Anda juga dapat membaca berita serupa dengan ini yang kami kumpulkan dari sumber berita lain.

A Big, Fatty Opportunity for Big PharmaA Big, Fatty Opportunity for Big PharmaThe next multibillion-dollar therapeutic area for drug companies may be fatty liver disease, but there are a few practical hurdles to overcome first.
Baca lebih lajut »

Samsung Faces Resistance From Big Pharma in the U.S.Samsung Faces Resistance From Big Pharma in the U.S.Samsung’s foray into the U.S. biologic-drug market is proving tougher than expected, as the South Korean company faces strong resistance from established pharmaceutical companies while doctors and patients are reluctant to switch to biosimilars.
Baca lebih lajut »

Posh And Purposeful: The Hottest Luxury Cars For 2019 Are Pickup TrucksPosh And Purposeful: The Hottest Luxury Cars For 2019 Are Pickup TrucksBig pickups mean big profits for automakers, especially the current crop of luxury-equipped haulers that start in the $50,000 range and can extend well beyond $60,000 and even $70,000 when fully loaded.
Baca lebih lajut »

The Exchange: Big Weed's big yearThe Exchange: Big Weed's big yearListen: Bruce Linton runs the world's biggest cannabis producer, Canopy Growth. He visited Breakingviews to discuss what's coming down the pipe in 2019, why a $100 bln weed company is still some way off, and why he doesn't actually partake - yet.
Baca lebih lajut »

From Amgen to Gilead, drugmakers are sitting on billions of cash — and top pharma executives are hinting about big M&A to come in 2019From Amgen to Gilead, drugmakers are sitting on billions of cash — and top pharma executives are hinting about big M&A to come in 2019Billion-dollar deals from drug giants Eli Lilly & Co. and Bristol-Myers Squibb could set the tone for a year full of healthcare acquisitions.
Baca lebih lajut »

Sen. Bernie Sanders says 'we will end' Big Pharma 'greed' in legislative push to cut drug pricesSen. Bernie Sanders says 'we will end' Big Pharma 'greed' in legislative push to cut drug pricesThe bills, led by Sanders and Reps. Elijah Cummings and Ro Khanna, would permit Health and Human Services Secretary Alex Azar to negotiate lower prices for drugs under Medicare Part D, the federal program for prescription drug benefits.
Baca lebih lajut »



Render Time: 2025-04-04 10:01:11